Europe Breast Biopsy Market

Europe Breast Biopsy Market Size (2023 to 2028)

As per the research report, the Europe Breast Biopsy Market size has been estimated at USD 154.79 million in 2023. This value is further forecasted to be growing at a CAGR of 10.6% and worth USD 256.17 million by 2028.

A breast biopsy is a process that involves extracting tissue or fluid from a suspect area of the patient's body and evaluating the sample for breast cancer.

The European breast biopsy market is majorly driven by the increasing prevalence of breast cancer and technological advancements in the healthcare sector across Europe. As a result, breast cancer is getting increasingly common in Europe, particularly among those over the age of 40, significantly influencing the market. Also, the increasing awareness of the breast cancer screening program is boosting the market growth. 

In addition, minimally invasive biopsy techniques are becoming more widely available in the market, which is expected to accelerate the market growth. In recent years, the demand for minimally invasive surgeries and image-guided needle biopsies has been significantly growing.  On the other hand, the initiative taken by the government for creating awareness among the people about the breast cancer screening program through medical tourism across the region is positively influencing the market growth.

Other factors such as increasing healthcare expenditure, availability of advanced healthcare sectors, and favorable reimbursement policies contribute to the regional market growth. Furthermore, the new product approvals launched by the key market players are expanding the market growth. In addition, the key market strategies such as partnerships, mergers, and acquisitions help the market develop. The growing adoption of advanced imaging equipment is expected to support the market growth. 

However, the High cost, unclear reimbursement rules, and high cost of treatments are forecasted to hamper the market growth. In addition, breast biopsy methods are connected to a range of unresolved regulatory issues and the risk of infection. Furthermore, the risk of infection from improper breast biopsy cut and wound care and uncertain regulatory guidelines for medical devices is expected to hinder growth in the European breast biopsy market.

This research report on the European breast biopsy market has been segmented and sub-segmented into the following categories:

By Type: 

• Open Surgical Breast Biopsy
• Needle Breast Biopsy

By Product: 

• Biopsy Tables
• Localization Wires
• Biopsy Needles
• Guidance Systems
• Others

By Guidance: 

• MRI-Guided Breast Biopsy
• Mammography-Guided Stereotactic Breast Biopsy
• Ultrasound-Guided Breast Biopsy
• Other Techniques

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Europe held the second-largest share of the global breast biopsy market in 2020, and it is anticipated to witness a significant share during the forecast period. The regional market growth is attributed to the availability of advanced technology, high healthcare expenditure, presence of key market players, and favorable reimbursement policies. In addition, emerging countries such as the United Kingdom, Germany, and Spain are significantly expanding the regional market growth an exponential market share.

Germany held the majority share of the European breast biopsy market in 2020 and is anticipated to continue dominating throughout the forecast period. The increasing prevalence of breast cancer among women in the region, technological advancements, and growing minimally invasive procedures.

Similarly, the UK is likely to witness a considerable share in the EU market due to the rapid adoption of technology innovations, increased awareness of breast cancer screening programs, and supportive government policies.

Furthermore, the countries such as France, Italy, and Spain are projected to showcase promising and contribute to the regional market expansion. The governments in these countries are creating medical tourism to create awareness among the people about cancer prevalence. The availability of advanced treatment options in the market is helping the market grow. In addition, Product launches, improving the healthcare sector, and growing healthcare spending are propelling the market growth.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the European breast biopsy market profiled in this report are Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.